Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec 1;60(12):813-822.
doi: 10.1097/RLI.0000000000001197.

Commercially Available Ultrasound Contrast Agents: Factors Contributing to Favorable Outcomes With Ultrasound-Mediated Drug Delivery and Ultrasound Localization Microscopy Imaging

Joshua J Hawley  1 , Sophie L Allen, David M Thompson, Adam J Schwarz, François J M Tranquart
Affiliations
Review

Commercially Available Ultrasound Contrast Agents: Factors Contributing to Favorable Outcomes With Ultrasound-Mediated Drug Delivery and Ultrasound Localization Microscopy Imaging

Joshua J Hawley et al. Invest Radiol. .

Abstract

Ultrasound contrast agents (UCAs) are microbubbles comprising an inert gas core stabilized by an encapsulating shell, which serves to increase the signal-to-noise ratio of blood-to-tissue in diagnostic ultrasound imaging. More recently, research has investigated the use of UCAs to combine both diagnostics and therapeutic outcomes in an amalgamated approach, designated 'theranostics.' Two examples of theranostic based approaches include the use of super-resolution imaging with ultrasound localized microscopy (ULM) and ultrasound-mediated drug delivery (UMDD). Both ULM and UMDD have been shown to have the potential to improve both patient care and clinical outcomes. Currently, there are 4 commercially available global UCAs licensed for clinical use. The physico-chemical properties of each of these UCAs influence its potential theranostic efficacy. Because of differences in their composition and/or manufacturing processes, each UCA has different characteristics that contribute to different i n vivo resonance behavior, which in turn influences their effective clinical applications. This review highlights the key physico-chemical characteristic differences of the 4 commercially available contrast agents, with specific emphasis on their gaseous core, shell composition, and microbubble volume distribution, while providing novel insights into their benefits for supporting emerging clinical technologies, specifically ULM and UMDD.

Keywords: microbubble; super-resolution imaging; theranostics; ultrasound contrast agent; ultrasound mediated drug delivery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: 4 of 5 authors (J.J.H., S.L.A., D.M.T., A.J.S.) are current employees of GE HealthCare; the manufacturer of Sonazoid and Optison. One author (F.J.M.T.) has been a prior employee of GE HealthCare and Bracco Imaging.

References

    1. Sirsi S, Borden M. Microbubble compositions, properties and biomedical applications. Bubble Sci Eng Technol. 2009;1(1–2):3–17.
    1. Frinking P, Segers T, Luan Y, et al. Three decades of ultrasound contrast agents: a review of the past, present and future improvements. Ultrasound Med Biol. 2020;46:892–908.
    1. Wood SC, Antony S, Brown RP, et al. Effects of ultrasound and ultrasound contrast agent on vascular tissue. Cardiovasc Ultrasound. 2012;10:29.
    1. Frinking PJ, Bouakaz A, Kirkhorn J, et al. Ultrasound contrast imaging: current and new potential methods. Ultrasound Med Biol. 2000;26:965–975.
    1. Rafter P, Phillips P, Vannan MA. Imaging technologies and techniques. Cardiol Clin. 2004;22:181–197.

LinkOut - more resources